ADDEX THERAPEUTICS LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0716 CHF | +4.99% |
|
+3.47% | +55.65% |
| May. 08 | Addex to Present at BioEURquity Europe 2024 | DJ |
| Apr. 30 | European Equities Traded in the US as American Depositary Receipts Decline | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 43.44 | 53.24 | 39.42 | 10.39 | 6.181 | 9.183 | - | - |
| Enterprise Value (EV) 1 | 12.06 | 34.48 | 19.4 | 3.801 | 2.66 | 13.46 | 13.73 | 9.183 |
| P/E ratio | -2.93 x | -4.15 x | -2.31 x | -0.22 x | -0.33 x | -1.19 x | -1.43 x | -1.79 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.7 x | 13.7 x | 12.5 x | 7.19 x | 3.75 x | 6.12 x | 6.12 x | 6.12 x |
| EV / Revenue | 4.37 x | 8.89 x | 6.15 x | 2.63 x | 1.62 x | 8.97 x | 9.15 x | 6.12 x |
| EV / EBITDA | -0.85 x | -2.91 x | -1.28 x | -0.19 x | -0.27 x | -2.03 x | -1.02 x | -3.67 x |
| EV / FCF | -1.27 x | -2.82 x | -1.32 x | -0.23 x | -0.33 x | -2.8 x | -3.61 x | -3.28 x |
| FCF Yield | -78.8% | -35.5% | -76% | -432% | -301% | -35.7% | -27.7% | -30.5% |
| Price to Book | 1.71 x | 3.69 x | 2.33 x | 1.58 x | 5.05 x | 7.16 x | -7.16 x | -7.16 x |
| Nbr of stocks (in thousands) | 26,485 | 26,754 | 37,903 | 103,234 | 134,374 | 128,257 | - | - |
| Reference price 2 | 1.640 | 1.990 | 1.040 | 0.1006 | 0.0460 | 0.0716 | 0.0716 | 0.0716 |
| Announcement Date | 4/8/20 | 3/11/21 | 3/10/22 | 3/30/23 | 4/18/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.763 | 3.879 | 3.153 | 1.445 | 1.647 | 1.5 | 1.5 | 1.5 |
| EBITDA 1 | -14.27 | -11.86 | -15.16 | -20.2 | -9.975 | -6.642 | -13.5 | -2.5 |
| EBIT 1 | -14.6 | -12.24 | -15.51 | -20.52 | -10.28 | -6.642 | -13.58 | -2.5 |
| Operating Margin | -528.56% | -315.62% | -491.79% | -1,420.07% | -624.23% | -442.79% | -905.33% | -166.67% |
| Earnings before Tax (EBT) 1 | -14.78 | -12.86 | -15.35 | -20.8 | -10.56 | -4.8 | -3.8 | -2.8 |
| Net income 1 | -14.78 | -12.86 | -15.35 | -20.8 | -10.56 | -4.8 | -3.8 | -2.8 |
| Net margin | -534.96% | -331.5% | -486.9% | -1,439.72% | -640.92% | -320% | -253.33% | -186.67% |
| EPS 2 | -0.5600 | -0.4800 | -0.4500 | -0.4600 | -0.1400 | -0.0600 | -0.0500 | -0.0400 |
| Free Cash Flow 1 | -9.511 | -12.24 | -14.74 | -16.44 | -7.999 | -4.8 | -3.8 | -2.8 |
| FCF margin | -344.21% | -315.53% | -467.39% | -1,137.56% | -485.69% | -320% | -253.33% | -186.67% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 4/8/20 | 3/11/21 | 3/10/22 | 3/30/23 | 4/18/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q2 | 2023 Q3 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.7578 | 0.4009 | 0.244 | 0.186 | 0.4157 | - | 0.329 | 0.1534 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.576 | -4.275 | -5.763 | -7.092 | -4.167 | - | -2.652 | -2.682 |
| Operating Margin | -471.9% | -1,066.3% | -2,361.89% | -3,812.9% | -1,002.4% | - | -806.08% | -1,748.07% |
| Earnings before Tax (EBT) 1 | -3.598 | -4.424 | -5.824 | -7.221 | -4.108 | - | -2.617 | -2.857 |
| Net income 1 | -3.598 | -4.424 | -5.824 | -7.221 | -4.108 | -2.675 | -2.617 | -2.857 |
| Net margin | -474.81% | -1,103.46% | -2,386.89% | -3,882.26% | -988.12% | - | -795.44% | -1,861.74% |
| EPS 2 | -0.1100 | -0.1300 | -0.1500 | -0.1900 | -0.0900 | -0.0400 | -0.0300 | -0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/10/22 | 5/5/22 | 7/30/22 | 11/11/22 | 8/10/23 | 11/29/23 | 4/18/24 |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 4.28 | 4.55 | - |
| Net Cash position 1 | 31.4 | 18.8 | 20 | 6.58 | 3.52 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | -0.6437 x | -0.3368 x | - |
| Free Cash Flow 1 | -9.51 | -12.2 | -14.7 | -16.4 | -8 | -4.8 | -3.8 | -2.8 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 0.9600 | 0.5400 | 0.4500 | 0.0600 | 0.0100 | 0.0100 | -0.0100 | -0.0100 |
| Cash Flow per Share | -0.3600 | -0.4600 | -0.4300 | - | - | - | - | - |
| Capex | - | 0.06 | 0.03 | 0 | - | - | - | - |
| Capex / Sales | - | 1.53% | 1% | 0.04% | - | - | - | - |
| Announcement Date | 4/8/20 | 3/11/21 | 3/10/22 | 3/30/23 | 4/18/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
SELL
Number of Analysts
2
Last Close Price
0.0716
CHF
Average target price
0.16
CHF
Spread / Average Target
+123.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.65% | 10.16M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ADXN Stock
- Financials Addex Therapeutics Ltd
